Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 1 h ago

Cadrenal Therapeutics, Inc.: Baggett Benjamin Matthew Wall discloses a stake of more than 5% (Schedule 13G)

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 17 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Baggett Benjamin Matthew Wall disclosed a stake exceeding 5% in Cadrenal Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0002163771-26-000002). The filing signals that the investor has crossed the threshold requiring public disclosure of a passive position in the clinical-stage biopharmaceutical company. The exact share count and percentage were not specified in the filing summary. Investors will watch for further 13G amendments or 13D filings that could indicate a shift from passive to activist intent.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Baggett Benjamin Matthew Wall, Cadrenal Therapeutics, Inc.